Spots Global Cancer Trial Database for Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
Official Title: A Phase I Study of TQB2928 Injection in Patients With Advanced Cancers
Study ID: NCT05192512
Conditions
Interventions
Study Description
Brief Summary: TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα (Signal Regulatory Protein Alpha) and enhances the phagocytosis of cancer cells by macrophages. This is a study to evaluate the safety, tolerability and effectiveness of TQB2928 injection in subjects with advanced malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun Yat-sen University Cancer Cen, Guangzhou, Guangdong, China
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
